Canine hyperlipidaemia.
Xenoulis PG, Steiner JM.
J Small Anim Pract. 2015 Oct;56(10):595-605. doi: 10.1111/jsap.12396.
Endocrine diseases as causes of secondary hyperlipidemia.
Bułdak Ł, Marek B, Kajdaniuk D, Urbanek A, Janyga S, Bołdys A, Basiak M, Maligłówka M, Okopień B.
Endokrynol Pol. 2019;70(6):511-519. doi: 10.5603/EP.a2019.0041.
Lipid metabolism and classification of hyperlipaemias.
Real JT, Ascaso JF.
Clin Investig Arterioscler. 2021 May;33 Suppl 1:3-9. doi: 10.1016/j.arteri.2020.12.008.
[Hyperlipidemia].
Márk L.
Orv Hetil. 2006 Jul 9;147(27):1284-5.
[Hyperlipidemia and osteoarticular manifestations].
Goupille P, Soutif D, Fouquet B, Valat JP.
Rev Med Interne. 1991 Mar-Apr;12(2):146-52. doi: 10.1016/s0248-8663(05)81380-3.
Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK.
Ann Med. 2022 Dec;54(1):1287-1296. doi: 10.1080/07853890.2022.2059559.
Statin-fibrate combination: therapy for hyperlipidemia: a review.
Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB.
Curr Med Res Opin. 2003;19(3):155-68. doi: 10.1185/030079903125001668.
Comprehensive Role of GDF15 in Inhibiting Adipogenesis and Hyperlipidemia, Enhancing Cardiovascular Health and Alleviating Inflammation in Metabolic Disorders.
Nayak N, Mukherjee T, Pattnaik A.
Curr Pharm Des. 2024;30(30):2387-2399. doi: 10.2174/0113816128318741240611114448.
[Hyperlipidemia management in Slovakia: observational study].
Fábryová U, Nemcová A.
Vnitr Lek. 2020 Winter;65(12):761-769.
Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms.
Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A.
J Cell Physiol. 2018 Jan;233(1):141-152. doi: 10.1002/jcp.25756. Epub 2017 Jun 6.
